2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. The Journal Of Clinical Psychiatry 2015, 76: 1535-45. PMID: 26581028, DOI: 10.4088/jcp.14m09320.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialTreatment outcomesClinical Antipsychotic TrialsBaseline characteristicsTreatment continuationCATIE trialAntipsychotic pharmacotherapyPrognostic subgroupsEffectiveness trialAntipsychotic TrialsLogistic regressionROC analysisMonths of treatmentImportant treatment outcomesDSM-IV diagnosisPatients' social isolationNegative Syndrome ScaleSocial isolationPoor outcomeZiprasidone treatmentAntipsychotic treatmentComorbid depressionSide effectsPsychosocial factorsSyndrome Scale
2014
Prognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroups